Clinical characteristics and outcomes in extreme elderly (age ≥ 85 years) Japanese patients with atrial fibrillation: The Fushimi AF registry

Chest

Volumn 149, Issue 2, 2016, Pages 401-412

  Yamashita, Yugo ^a   Hamatani, Yasuhiro ^a   Esato, Masahiro ^b   Chun, Yeong Hwa ^b   Tsuji, Hikari ^c   Wada, Hiromichi ^a   Hasegawa, Koji ^a   Abe, Mitsuru ^a   Lip, Gregory Y H ^d,e   Akao, Masaharu ^a  

^a NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^b Ijinkai Takeda General Hospital   (Japan)

^c Tsuji Clinic   (Japan)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e AALBORG UNIVERSITY   (Denmark)

Author keywords

Atrial fibrillation; Cardiology; Stroke

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; WARFARIN;

ADULT; AGE DISTRIBUTION; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BODY MASS; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CLINICAL FEATURE; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE REGISTRY; EMBOLISM; FEMALE; FOLLOW UP; HAS BLED SCORE; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; JAPANESE (PEOPLE); MAJOR BLEEDING; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC EMBOLISM; THROMBOEMBOLISM; VERY ELDERLY; CLINICAL TRIAL; COMPLICATION; JAPAN; MULTICENTER STUDY; PROGNOSIS; REGISTER; RISK FACTOR; STROKE;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; EMBOLISM; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; JAPAN; MALE; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; STROKE;

EID: 84958074096     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.15-1095     Document Type: Article

References (30)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370-2375.
2. Camm AJ, Kirchhof P, Lip GY, et al; European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-2429.
3. Pisters R, Lane DA, Marin F, Camm AJ, Lip GY. Stroke and thromboembolism in atrial fibrillation. Circ J. 2012;76(10): 2289-2304.
4. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867.
5. Camm AJ, Lip GY, De Caterina R, et al; ESC Committee for Practice Guidelines-CPG; Document Reviewers. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14(10): 1385-1413.
6. Hylek EM, D'Antonio J, Evans-Molina C, Shea C, Henault LE, Regan S. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke. 2006;37(4): 1075-1080.
7. Waldo AL, Becker RC, Tapson VF, Colgan KJ; NABOR Steering Committee. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol. 2005;46(9):1729-1736.
8. Nieuwlaat R, Capucci A, Lip GY, et al; Euro Heart Survey Investigators. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2006;27(24): 3018-3026.
9. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7): 638-645.
10. Akao M, Chun YH, Wada H, et al; Fushimi AF Registry Investigators. Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry. J Cardiol. 2013;61(4): 260-266.
11. Akao M, Chun YH, Esato M, et al; Fushimi AF Registry Investigators. Inappropriate use of oral anticoagulants for patients with atrial fibrillation. Circ J. 2014;78(9):2166-2172.
12. Japanese Society of Nephrology. Evidencebased practice guideline for the treatment of CKD. Clin Exp Nephrol. 2009;13(6): 537-566.
13. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013). Circ J. 2014;78(8):1997-2021.
14. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22): 2864-2870.
15. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263-272.
16. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-1100.
17. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694.
18. Furusho H, Takamura M, Takata S, et al. Current status of anticoagulation therapy for elderly atrial fibrillation patients in Japan: from Hokuriku Atrial Fibrillation Trial. Circ J. 2008;72(12): 2058-2061.
19. Siu CW, Tse HF. Net clinical benefit of warfarin therapy in elderly Chinese patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2014;7(2): 300-306.
20. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343(8899):687-691.
21. Copland M, Walker ID, Tait RC. Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation. Arch Intern Med. 2001;161(17):2125-2128.
22. Pengo V, Legnani C, Noventa F, Palareti G; ISCOAT Study Group (Italian Study on Complications of Oral Anticoagulant Therapy). Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A multicenter inception cohort study. Thromb Haemost. 2001;85(3):418-422.
23. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol. 2009;54(11):999-1002.
24. Poli D, Antonucci E, Testa S, Tosetto A, Ageno W, Palareti G; Italian Federation of Anticoagulation Clinics. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation. 2011;124(7): 824-829.
25. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115(21):2689-2696.
26. Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost. 2011;106(4):739-749.
27. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012;107(3):584-589.
28. van Walraven C, Hart RG, Connolly S, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the Atrial Fibrillation Investigators. Stroke. 2009;40(4):1410-1416.
29. Lip GY, Lane DA. Stroke prevention with oral anticoagulation therapy in patients with atrial fibrillation-focus on the elderly. Circ J. 2013;77(6):1380-1388.
30. Lip GY, Clementy N, Pericart L, Banerjee A, Fauchier L. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project. Stroke. 2015;46(1):143-150.